Current SoC for BPDCN and other emerging treatment options
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, summarizes the current standard of care (SoC) for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp, a first-in-class CD123-targeted agent, is particularly efficacious for first-line adult patients with BPDCN. Dr Papayannidis highlights that allogeneic stem cell transplantation (alloSCT) is utilized in virtually all cases of BPDCN following standard chemotherapy regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.